Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old

20260 citationsJournal Articlehybrid Open Access

Authors

Patricia Winokur · University of Iowa

Oyeniyi Diya · Pfizer (United States)

David Fitz-Patrick · East–West Center

Michael K. Dever · Orlando Clinical Research Center

Juleen Gayed · Pfizer (United States)

Stephen Lockhart · Pfizer (United States)

Xia Xu ·

Abstract

Bivalent and monovalent BA.1‒adapted vaccines had a safety profile similar to original BNT162b2 30 μg and induced substantial neutralizing responses against Omicron BA.1 and ancestral strains.NCT04955626.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research Animal Virus Infections Studies COVID-19 Clinical Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Infectious Diseases

DOI: 10.1093/cid/ciag026

Field-Weighted Citation Impact: 0.00